Background: The effectiveness of cancer control is unclear after radical prostatectomy for patients with clinical T3 prostate cancer. Methods: We retrospectively reviewed 1409 patients who underwent radical prostatectomy between April 2007 and December 2014, including 210 patients with cT3 prostate cancer. Nine patients who received neoadjuvant hormonal therapy and three patients who were lost to followup were excluded from the analysis. Clinical staging was performed by an experienced radiologist using preoperative magnetic resonance imaging findings. We analyzed the predictors of biochemical recurrence using Cox proportional hazard analyses. Results: A total of 113 patients (57%) underwent radical retropubic prostatectomy and 85 patients (43%) underwent robot-assisted radical prostatectomy. The median follow-up period was 36 months. Downstaging occurred for 60 patients (30%), positive surgical margins were identified in 117 patients (59%), and biochemical recurrence was observed for 89 patients (45%). In the multivariate analyses, the independent preoperative predictors of biochemical recurrence were ≥50% proportion of positive biopsy cores [hazard ratio (HR): 2.858, P < 0.0001] and a biopsy Gleason score of ≥8 (HR: 1.800, P = 0.0093). The independent post-operative predictors of biochemical recurrence were positive surgical margins (HR: 2.490, P = 0.0018) and seminal vesicle invasion (HR: 2.750, P < 0.0001). Conclusions: Among patients with cT3 prostate cancer, the percentage of positive biopsy cores and the biopsy Gleason score should be considered to select treatment. Compared with radical retropubic prostatectomy, robot-assisted radical prostatectomy may be a feasible treatment option in this setting.
Introduction
Approximately 160 000 new cases of prostate cancer are expected to be diagnosed in 2017 (1) , and the patients' prognoses are related to their stage at diagnosis and subsequent treatment. Locally advanced prostate cancer is defined as cancer that has extended clinically beyond the prostatic capsule with invasion of the pericapsular tissue, apex, bladder neck and/or seminal vesicle. Although most cases are diagnosed with localized disease, approximately 20% are diagnosed at the clinical T3 stage (2) . Furthermore, patients with high-risk prostate cancer have an increased risk of prostate-specific antigen (PSA) failure, which can require secondary therapy. Locally advanced disease remains a common clinical challenge and its management remains controversial. Although radical prostatectomy (RP) is appropriate for any patient whose cancer appears to be clinically localized to the prostate, RP has been discouraged for highrisk prostate cancer because of concerns regarding adverse effects and high rates of biochemical recurrence (BCR) (3) . Nevertheless, several recent reports have suggested that RP is effective for cases with cT3 disease (4) (5) (6) (7) (8) , and there have been noticeable improvements in the surgical techniques for RP. For example, the first robot-assisted radical prostatectomy (RARP) was performed in 2000, and RARP has subsequently become a widely used technique. However, there is no consensus regarding the optimal treatment and oncological outcomes for patients with cT3 prostate cancer, and no studies have examined the effects of RARP in this setting. Therefore, the present study evaluated the effectiveness of cancer control using radical retropubic prostatectomy (RRP) or RARP among patients with cT3 prostate cancer.
Materials and methods
This study's retrospective protocol was approved by the appropriate institutional review board. We retrospectively reviewed 1 409 patients who underwent RP between April 2007 and December 2014 at our institution, including 210 patients with cT3 prostate cancer. However, we excluded nine patients who received neoadjuvant hormonal therapy (NHT) and three patients who were lost to follow-up. Thus, 198 patients were included in this study (Fig. 1) . Clinical staging was performed before the prostate biopsy by an experienced radiologist using preoperative magnetic resonance imaging findings, which included T2-weighted images, diffusionweighted images and apparent diffusion coefficient maps. The RP was performed by various surgeons using standard techniques for RRP or RARP, and all patients underwent pelvic lymphadenectomy. The 2005 International Society of Urological Pathology consensus conference criteria were used to determine the pathological staging. The primary outcome was BCR, which was identified based on a post-operative serum PSA level of ≥0.2 ng/ml. Univariate and multivariate Cox regression models were used to analyze the predictors of BCR. All statistical analyses were performed using JMP ® software (version 12; SAS Institute Inc., Cary, NC, USA), and differences were considered statistically significant at P values of <0.05.
Results Table 1 shows the characteristics of the 198 patients, including 113 patients (57%) who underwent RRP and 85 patients (43%) who underwent RARP. Positive surgical margins (PSMs) were detected in 117 patients (59%) and seminal vesicle invasion was detected in 47 patients (24%). Pathological downstaging to an organ-confined tumor was observed for 60 patients (30%). The median follow-up was 36 months (interquartile range: 18-57 months). Among the 198 patients, 89 patients (45%) developed BCR and 14 patients (7%) developed systemic progression. The median time to BCR was 34 months, and the Kaplan-Meier analysis revealed that the 5-year PSA-free survival rate was 32% (Fig. 2 ). Among the patients who developed BCR, 67 patients (75%) received salvage hormonal therapy, four patients (4%) received salvage radiotherapy and 12 patients (13%) received both salvage therapies. The multivariate analyses revealed that the independent preoperative predictors of BCR were ≥50% proportion of positive (Fig. 3) and a biopsy Gleason score of ≥8 (HR: 1.800, 95% CI: 1.154-2.864; P = 0.0093) ( Table 2) (Fig. 4) . The independent post-operative predictors of BCR were PSM (HR: 2.490, 95% CI: 1.386-4.764; P = 0.0018) and of seminal vesicle invasion were (HR: 2.750, 95% CI: 1.732-4.342; P < 0.0001) ( Table 3 ).
Discussion
The appropriate treatment for patients with locally advanced prostate cancer remains controversial, although RP in the present study provided favorable outcomes for some patients with cT3 prostate cancer, as 55% did not develop BCR after a median follow-up of 36 months. Furthermore, we found that the independent predictors of BCR were the percentage of positive biopsy cores, the biopsy Gleason score, PSM and seminal vesicle invasion. The surgical approach was a significant predictor of BCR in the univariate analyses, although its significance disappeared in the multivariate analysis. To the best of our knowledge, this is the first report to investigate a subgroup of patients with cT3 prostate cancer who underwent RARP.
Patients with high-risk prostate cancer have an elevated risk of cancer progression and may require salvage therapy. Thus, surgical treatment of cT3 prostate cancer has traditionally been discouraged (3), and some studies have indicated that external beam radiation therapy may be effective for high-risk and very high-risk cases (9) (10) (11) . Furthermore, the combination of external beam radiation therapy with androgen deprivation therapy improved overall survival. However, several previous reports have indicated that some patients with cT3 prostate cancer may benefit from RP (4-8). For example, Carver et al. evaluated patients with cT3 disease undergoing RRP (4), including some patients (36%) who received NHT and reported that the 10-year cancer-specific survival rate was 85%. In that study, BCR was independently predicted by the biopsy Gleason score, PSA level and year of surgery. Freedland et al. also evaluated the outcomes among 62 patients with cT3a prostate cancer who were treated using RRP (5), and reported that the PSA-doubling time at the time of recurrence was significantly associated with an increased risk of prostate cancer-related death.
There has been an evolution in the approach to RP, with RARP gradually displacing RRP as the gold-standard technique, as RARP provides the surgeon with a clearer magnified view of the prostatic and pelvic anatomy. Some studies have also revealed that RARP has efficacy that is comparable to that of RRP and laparoscopic RP (12, 13) . Thus, RARP appears to be a feasible option for men with high-risk prostate cancer, as the PSM rates have been considered similar for RARP and RRP (14) , although a recent review indicates that RARP provided better rates of PSM and BCR than RRP (15) .
Surgery offers other benefits, relative to radiotherapy alone, as an accurate histopathological diagnosis can only be made after RP. In this context, accurate staging of advanced disease is very important for determining the future management strategy. For example, the clinical T stage can be assigned incorrectly, and T-staging errors more commonly result in downstaging than upstaging (16) . In addition, approximately 30% of cT3 tumors are downstaged based on surgical findings (17) , and a similar rate was observed in the present study. Thus, Joniau et al. developed a table for the preoperative prediction of histopathological findings after RP (18) . In the present study, the percentage of positive biopsy cores independently predicted BCR, and Pierorazio et al. have also reported that positive core involvement predicted unfavorable pathological findings (19) . One recent review studied the role of NHT before prostatectomy (22) . Although NHT significantly reduced the rates of PSM and extra-prostatic extension, it was not associated with an improvement in overall survival. Nevertheless, NHT may be helpful for preoperative downstaging among patients with high-risk cancer.
The present study is limited by its single-center retrospective design and small sample size. Thus, large-scale multicenter studies are needed to validate our findings. Nevertheless, the present study revealed that, among patients with cT3 prostate cancer, BCR was independently associated with preoperative PSA, the percentage of positive biopsy cores and the biopsy Gleason score. Therefore, these factors should be considered when planning treatment in this setting.
Conclusion
Among patients with cT3 prostate cancer, the percentage of positive biopsy cores and the biopsy Gleason score should be considered to select treatment. Compared with RRP, RARP may be a feasible option for treating patients with cT3 prostate cancer.
